Suppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirus-encoding endostatin

Cancer Gene Therapy

Volumn 17, Issue 1, 2010, Pages 49-57

  Yang, L ^a   Wang, L ^a,b   Su, X Q ^a   Chen, X C ^a   Li, D ^a   Luo, S T ^a   Shi, H S ^a   Chen, L J ^a   Wang, Y S ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Adenovirus; Endostatin; Gene therapy; Ovarian cancer; PEG PE liposome

Indexed keywords

1,2 DIOLEOYL 3 PHOSPHATIDYLETHANOLAMINE; 1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; ENDOSTATIN; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G ANTIBODY; LIPOSOME; LIPOSOME ENCAPSULATED RECOMBINANT HUMAN ENDOSTATIN ADENOVIRUS VECTOR; PHOSPHATIDYLETHANOLAMINE; RNA; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADENOVIRUS 5; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER GENE THERAPY; CANCER INHIBITION; CELL STRAIN; CELL STRAIN HEK293; CELL STRAIN SKOV 3; CONTROLLED STUDY; DRUG SCREENING; DRUG TOLERABILITY; ELECTRON MICROSCOPY; ENCAPSULATION; ENDOSTATIN GENE; FEMALE; GENE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOSOMAL GENE DELIVERY SYSTEM; LONG TERM CARE; MOLECULAR CLONING; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; ENDOSTATINS; FEMALE; GENE THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LIPOSOMES; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; RECEPTORS, VIRUS; TRANSFECTION;

ADENOVIRIDAE; MUS;

EID: 72449152641     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.47     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
3. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999; 59: 4770-4775.
4. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998; 90: 447-454.
5. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
6. Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme VP. Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 1999; 258: 345-352.
7. Dixelius J, Cross M, Matsumoto T, Sasaki T, Timpl R, Claesson-Welsh L. Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res 2002; 62: 1944-1947.
8. Hanai J, Dhanabal M, Karumanchi SA, Albanese C, Waterman M, Chan B et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 2002; 277: 16464-16469.
9. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangio-genic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
10. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micro-metastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-153.
11. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-692.
12. Crystal RG. The body as a manufacturer of endostatin. Nat Biotechnol 1999; 17: 336-337.
13. Ogura T, Kobayashi H, Ueoka Y, Okugawa K, Kato K, Hirakawa T et al. Adenovirus-mediated calponin h1 gene therapy directed against peritoneal dissemination of ovarian cancer: bifunctional therapeutic effects on peritoneal cell layer and cancer cells. Clin Cancer Res 2006; 12: 5216-5223.
14. Russell W. Adenovirus gene therapy for ovarian cancer. J Natl Cancer Inst 2002; 94: 706-707.
15. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8: 42-51.
16. Dummer R, Hassel JC, Fellenberg F, Eichmuller S, Maier T, Slos P et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 2004; 104: 1631-1638.
17. Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adeno-virus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005; 11: 7444-7453.
18. Li HL, Li S, Shao JY, Lin XB, Cao Y, Jiang WQ et al. Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors. Gene Therapy 2008; 15: 247-256.
19. Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL et al. Safety of local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002; 13: 15-63. (Pubitemid 34075172)
20. Shirakawa T, Terao S, Hinata N, Tanaka K, Takenaka A, Hara I et al. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory meta-static prostate cancer. Hum Gene Ther 2007; 18: 1225-1232.
21. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
22. Brody SL, Metzger M, Danel C, Rosenfeld MA, Crystal RG. Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gene Ther 1994; 5: 821-836. (Pubitemid 24310569)
23. Kaplan JM, St George JA, Pennington SE, Keyes LD, Johnson RP, Wadsworth SC et al. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Therapy 1996; 3: 117-127.
24. Jooss K, Ertl HC, Wilson JM. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol 1998; 72: 2945-2954.
25. Yotnda P, Chen DH, Chiu W, Piedra PA, Davis A, Templeton NS et al. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 2002; 5: 233-241.
26. Steel JC, Cavanagh HM, Burton MA, Abu-Asab MS, Tsokos M, Morris JC et al. Increased tumor localization and reduced immune response to adenoviral vector formulated with the liposome DDAB/DOPE. Eur J Pharm Sci 2007; 30: 398-405.
27. Raja-Walia R, Webber J, Naftilan J, Chapman GD, Naftilan AJ. Enhancement of liposome-mediated gene transfer into vascular tissue by replication deficient adeno-virus. Gene Therapy 1995; 2: 521-530.
28. Qiu C, De Young MB, Finn A, Dichek DA. Cationic liposomes enhance adenovirus entry via a pathway independent of the fiber receptor and alpha(v)-integrins. Hum Gene Ther 1998; 9: 507-520.
29. Steel JC, Cavanagh HM, Burton MA, Kalle WH. Micro-sphere-liposome complexes protect adenoviral vectors from neutralising antibody without losses in transfection efficiency, in-vitro. J Pharm Pharmacol 2004; 56: 1371-1378.
30. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
31. Chillon M, Lee JH, Fasbender A, Welsh MJ. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Therapy 1998; 5: 995-1002.
32. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553-566. (Pubitemid 34734419)
33. Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2000; 2: 524-530.
34. Hemminki A, Belousova N, Zinn KR, Liu B, Wang M, Chaudhuri TR et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 2001; 4: 223-231.
35. Cripe TP, Dunphy EJ, Holub AD, Saini A, Vasi NH, Mahller YY et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res 2001; 61: 2953-2960.
36. Raschperger E, Thyberg J, Pettersson S, Philipson L, Fuxe J, Pettersson RF. The coxsackie-and adenovirus receptor (CAR) is an in vivo marker for epithelial tight junctions, with a potential role in regulating permeability and tissue home-ostasis. Exp Cell Res 2006; 312: 1566-1580.
37. Kreuzer J, Denger S, Reifers F, Beisel C, Haack K, Gebert J et al. Adenovirus-assisted lipofection: efficient in vitro gene transfer of luciferase and cytosine deaminase to human smooth muscle cells. Atherosclerosis 1996; 124: 49-60.
38. Sung MW, Lee SG, Yoon SJ, Lee HJ, Heo DS, Kim KH et al. Cationic liposome-enhanced adenoviral gene transfer in a murine head and neck cancer model. Anticancer Res 2000; 20: 1653-1656.
39. Fasbender A, Zabner J, Chillon M, Moninger TO, Puga AP, Davidson BL et al. Complexes of adenovirus with poly-cationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 1997; 272: 6479-6489.
40. Lee SG, Yoon SJ, Kim CD, Kim K, Lim DS, Yeom YI et al. Enhancement of adenoviral transduction with polycationic liposomes in vivo. Cancer Gene Ther 2000; 7: 1329-1335.
41. Byk T, Haddada H, Vainchenker W, Louache F. Lipofecta-mine and related cationic lipids strongly improve adenoviral infection efficiency of primitive human hematopoietic cells. Hum Gene Ther 1998; 9: 2493-2502.
42. Lee EM, Hong SH, Lee YJ, Kang YH, Choi KC, Choi SH et al. Liposome-complexed adenoviral gene transfer in cancer cells expressing various levels of coxsackievirus and adenovirus receptor. J Cancer Res Clin Oncol 2004; 130: 169-177.
43. Natsume A, Mizuno M, Ryuke Y, Yoshida J. Cationic liposome conjugation to recombinant adenoviral vector reduces viral antigenicity. Jpn J Cancer Res 2000; 91: 363-367.